Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein

被引:79
作者
Bowen, S
Tare, N
Inoue, T
Yamasaki, M
Okabe, M
Horii, I
Eliason, JF
机构
[1] Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA
[2] Hoffmann La Roche Inc, Roche Res Ctr, Drug Discovery, Nutley, NJ 07110 USA
[3] Nippon Roche Res Ctr, Dept Toxicol, Kamakura, Kanagawa 247, Japan
[4] Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan
[5] Kyowa Hakko Kogyo Co Ltd, Div Pharmaceut Res & Dev, Tokyo 194, Japan
[6] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA
关键词
granulocyte colony; stimulating factor; neutrophils; in vivo; mutein;
D O I
10.1016/S0301-472X(98)00051-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Proteins conjugated with polyethylene glycol (PEG) have increased in vivo activity compared to native proteins. We examined the activity of a variety of PEG conjugates prepared with a recombinant mutein of granulocyte colony-stimulating factor (nartograstim [NTG], KW-2228), The total PEG mass was varied by the number and size of the PEG molecules conjugated, In vitro activity, determined using a proliferation assay with G-NFS-60 cells, demonstrated an inverse relationship between PEG mass and concentration required for half-maximal proliferation. In vivo activity was examined by injecting compounds subcutaneously into normal mice and determining neutrophil counts at various times. Initial experiments in C57BL/6J mice indicated that neutrophil levels were significantly elevated 5 days after a single injection of 25 mu g/mouse of each PEG-NTG preparation. More detailed experiments were performed with several of the preparations in C3H/HeJ mice lacking endotoxin receptors, The results demonstrated that the time after injection at which neutrophil numbers reached a maximum increased with increasing size of PEG. Similar results were obtained with purified preparations containing 1, 2, or 3 units of 20-kDa PEG per molecule of NTG, showing that increasing the extent of PEGylation also increases in vivo activity, Dose-response studies with the 20-kDa PEG-NTG demonstrated a plateau at doses >2.7 mu g/mouse at day 3, The plateau dose increased to 8.4 mu g/mouse at day 5, and no plateau was evident at the highest dose tested (50 mu g/mL) at days 7 and 10, These results demonstrate that elevated neutrophil levels can be maintained for extended periods following single administration of high-molecular-weight PEG-NTG, (C) 1999 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:425 / 432
页数:8
相关论文
共 24 条
[1]   Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals [J].
Anderlini, P ;
Przepiorka, D ;
Champlin, R ;
Korbling, M .
BLOOD, 1996, 88 (08) :2819-2825
[2]  
DEMETRI GD, 1991, BLOOD, V78, P2791
[4]  
Keating M J, 1993, Leuk Lymphoma, V10 Suppl, P153, DOI 10.3109/10428199309149129
[5]   Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor [J].
Kuwabara, T ;
Kobayashi, S ;
Sugiyama, Y .
DRUG METABOLISM REVIEWS, 1996, 28 (04) :625-658
[6]  
KUWABARA T, 1994, J PHARMACOL EXP THER, V271, P1535
[7]   Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells [J].
Kuwabara, T ;
Kobayashi, S ;
Sugiyama, Y .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (01) :E73-E84
[8]   RECEPTOR-MEDIATED CLEARANCE OF G-CSF DERIVATIVE NARTOGRASTIM IN BONE-MARROW OF RATS [J].
KUWABARA, T ;
UCHIMURA, T ;
KOBAYASHI, H ;
KOBAYASHI, S ;
SUGIYAMA, Y .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1995, 269 (01) :E1-E9
[9]   THE KINETICS OF HUMAN GRANULOPOIESIS FOLLOWING TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR INVIVO [J].
LORD, BI ;
BRONCHUD, MH ;
OWENS, S ;
CHANG, J ;
HOWELL, A ;
SOUZA, L ;
DEXTER, TM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (23) :9499-9503
[10]   CONTROL OF GRANULOCYTES AND MACROPHAGES - MOLECULAR, CELLULAR, AND CLINICAL ASPECTS [J].
METCALF, D .
SCIENCE, 1991, 254 (5031) :529-533